Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 13, 303-309
Abstract
No abstract availableKeywords
Funding Information
- Inserm (ANRS 13043)
- MIGAC
- CSL Behring, LLC
This publication has 18 references indexed in Scilit:
- Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphomaBone Marrow Transplantation, 2016
- Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialBlood, 2016
- CCR5Δ32 mutation and HIV infection: basis for curative HIV therapyCurrent Opinion in Virology, 2015
- Stem Cell Transplantation for Lymphoma Patients with HIV InfectionCell Transplantation, 2011
- Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantationBlood, 2011
- RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34 + Cells in Patients Undergoing Transplantation for AIDS-Related LymphomaScience Translational Medicine, 2010
- Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV‐Infected versus HIV‐Uninfected Patients with Relapsed or Refractory LymphomaClinical Infectious Diseases, 2010
- Pattern of cancer risk in persons with AIDS in Italy in the HAART eraBritish Journal of Cancer, 2009
- Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell TransplantationNew England Journal of Medicine, 2009
- Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2008